Spencer Feldman

CAR-T therapy for myeloma faces challenges in early-line use due to accessibility, eligibility criteria and long wait times, despite strong efficacy in trials.

Immune response data from FLAMINGO-01 shows positive results in patients with HER2+ breast cancer, suggesting potential for further treatment expansion.

Camrelizumab combo doubled the five-year survival rate in advanced squamous lung cancer, reducing mortality risk by 43%, in a Phase 3 trial.

The COCOON trial regimen reduced dermatologic side effects in patients with EGFR-mutant non-small cell lung cancer, phase 2 trial data showed.

The phase 3 trial showed relacorilant with chemotherapy improved progression-free and overall survival in platinum-resistant ovarian cancer.

FDA expands Pluvicto indication to adults with PSMA+ metastatic castration-resistant prostate cancer previously treated with androgen receptor inhibitors.

Favorable initial results from a phase 1/2 trial of solnerstotug in PD-L1–resistant tumors showed a 14% response rate and 62% disease control rate.

A progress report for a phase 1 trial of CLD-101 in recurrent glioma shows safety and feasibility at multiple intracerebral doses.

EVM14 received FDA clearance for clinical trials, marking Everest Medicines’ first in-house developed therapeutic to reach this stage.

The first patient has been dosed in the phase 3 TACTI-004 trial evaluating efti with Keytruda and chemotherapy for advanced non-small cell lung cancer.

The first patient was dosed in a phase 3 trial of IBI354 for platinum-resistant ovarian cancer with HER2 expression.

Dr. Zachariah H. Foda discusses key colorectal cancer warning signs, the rise in younger diagnoses and more.

First patient dosed in phase 1b/2a trial for castration-resistant metastatic prostate cancer, evaluating pocenbrodib alone and with other drug combinations.

FDA grants fast track designation to azer-cel, an allogeneic CAR T-cell therapy, for relapsed or refractory diffuse large B-cell lymphoma.

Gavreto is recommended as a first-line treatment for metastatic RET fusion-positive, metastatic non-small cell lung cancer, with potential severe side effects.

Elevation Oncology discontinues EO-3021 for gastric and gastroesophageal junction cancers after phase 1 trial shows insufficient efficacy.

Gene expression testing helps determine chemotherapy needs for HR+ breast cancer, optimizing treatment and reducing unnecessary toxicity.

The FDA has approved Keytruda plus chemotherapy in HER2+ gastric or GEJ adenocarcinoma with PD-L1–positive expression, based on KEYNOTE-811 data.

Genetic and genomic testing guide breast cancer risk assessment and treatment, as discussed by Dr. Mark Robson at the Miami Breast Cancer Summit.

Treatment with the T-cell immunotherapy Orca-T improved survival free of moderate-to-severe chronic graft-versus-host disease across leukemia subtypes.

Elahere shows consistent survival benefits in patients with folate receptor alpha-positive platinum-resistant ovarian cancer in the MIRASOL trial.

The FDA has granted orphan drug designation to PEP-010 for pancreatic cancer, advancing its development as a potential novel treatment for the disease.

Real-world data suggest Jakafi shows limited benefits in CALR-mutated myelofibrosis.

Jelmyto demonstrated long-term efficacy in low-grade upper tract urothelial carcinoma, with most maintaining complete response after several months.

Following the Bacillus Calmette-Guérin shortage, the first patient with bladder cancer has been dosed with recombinant Bacillus Calmette-Guérin in the U.S.

The first patients have been enrolled in the HEROES trial, exploring de-escalation of anti-HER2 therapy in metastatic HER2+ breast cancer using circulating tumor DNA.

RECKGIST score may predict recurrence in neurofibromatosis type 1 GISTs, potentially guiding treatment decisions, according to study findings.

Vepdegestrant improved progression-free survival in patients with estrogen receptor 1 mutations in advanced ER-positive, HER2-negative breast cancer.

Dr. Joseph Mikhael discusses early signs, treatments and supportive care for multiple myeloma in an interview with CURE.

Gleevec response in GIST varies by mutational profile, with KIT-exon-11 mutation linked to better outcomes, emphasizing mutation testing for treatment decisions.